Dataset from A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.本研究旨在基于研究者影像学评估，对比转移性肾细胞癌受试者接受AGS-16C3F与阿昔替尼治疗后的无进展生存期（progression free survival, PFS）